Analysts’ Recent Ratings Updates for Keros Therapeutics (KROS)

by · The Cerbat Gem

Several brokerages have updated their recommendations and price targets on shares of Keros Therapeutics (NASDAQ: KROS) in the last few weeks:

  • 11/7/2024 – Keros Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $84.00 price target on the stock.
  • 11/7/2024 – Keros Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
  • 11/5/2024 – Keros Therapeutics is now covered by analysts at Jefferies Financial Group Inc.. They set a “buy” rating on the stock.
  • 11/4/2024 – Keros Therapeutics was upgraded by analysts at Wedbush to a “strong-buy” rating.
  • 10/24/2024 – Keros Therapeutics is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating on the stock.
  • 10/16/2024 – Keros Therapeutics is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $77.00 price target on the stock.
  • 9/23/2024 – Keros Therapeutics is now covered by analysts at Guggenheim. They set a “buy” rating and a $96.00 price target on the stock.
  • 9/12/2024 – Keros Therapeutics had its price target lowered by analysts at Bank of America Co. from $81.00 to $76.00. They now have a “buy” rating on the stock.

Keros Therapeutics Trading Up 0.4 %

KROS stock traded up $0.24 during midday trading on Monday, hitting $68.15. The stock had a trading volume of 422,540 shares, compared to its average volume of 370,803. The firm has a market cap of $2.56 billion, a P/E ratio of -13.08 and a beta of 1.23. The business has a fifty day moving average price of $58.19 and a two-hundred day moving average price of $52.13. Keros Therapeutics, Inc. has a 1-year low of $27.31 and a 1-year high of $73.00.

Keros Therapeutics (NASDAQ:KROS – Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million during the quarter. During the same quarter last year, the company earned ($1.33) earnings per share. Keros Therapeutics’s revenue for the quarter was up 4750.0% compared to the same quarter last year. On average, equities analysts anticipate that Keros Therapeutics, Inc. will post -5.14 EPS for the current year.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares of the company’s stock, valued at $5,260,163.22. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 22.90% of the company’s stock.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KROS. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Keros Therapeutics by 1.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock valued at $870,000 after acquiring an additional 251 shares in the last quarter. GSA Capital Partners LLP raised its holdings in Keros Therapeutics by 25.5% during the first quarter. GSA Capital Partners LLP now owns 8,538 shares of the company’s stock worth $565,000 after buying an additional 1,736 shares during the last quarter. Swiss National Bank lifted its stake in shares of Keros Therapeutics by 22.0% in the first quarter. Swiss National Bank now owns 49,900 shares of the company’s stock valued at $3,303,000 after buying an additional 9,000 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Keros Therapeutics by 26.5% during the first quarter. ProShare Advisors LLC now owns 7,136 shares of the company’s stock valued at $472,000 after buying an additional 1,496 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Keros Therapeutics by 7.9% during the first quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock worth $102,329,000 after acquiring an additional 113,563 shares in the last quarter. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

See Also